In the US, Ponatinib (ponatinib systemic) is a member of the following drug classes: BCR-ABL tyrosine kinase inhibitors, multikinase inhibitors, VEGF/VEGFR inhibitors and is used to treat Acute Lymphoblastic Leukemia and Chronic Myelogenous Leukemia.
CAS registry number (Chemical Abstracts Service)
Antineoplastic agent: Tyrosine kinase inhibitor
- Ponatinibum (Latin)
- Ponatinib (German)
- Ponatinib (French)
- Ponatinib (Spanish)
- Ponatinib (OS: USAN)
- AP 24534 (IS)
- UNII-4340891KFS (IS)
- Ponatinib Hydrochloride (OS: USAN)
- AP 24534 hydrochloride (IS)
- UNII-96R6PU3D8J (IS)
ARIAD, Denmark; Ariad Pharma, Slovenia; Haupt Pharma Amareg, Slovakia
Ariad, Austria; Ariad, Ireland; Ariad, Norway; Ariad Pharma, Finland; Ariad Pharma, United Kingdom; Ariad Pharmaceuticals, France
|Rec.INN||Recommended International Nonproprietary Name (World Health Organization)|
|USAN||United States Adopted Name|
|WHO||World Health Organization|
Further information on drug naming conventions: International Nonproprietary Names.
Important Notice: The Drugs.com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.